BTIG Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $10

Benzinga Newsdesk www.benzinga.com Neutral 51.7%

Neg 0% Neu 51.7% Pos 0%

BTIG analyst Thomas Shrader maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and lowers the price target from $25 to $10.